Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T51803
(Former ID: TTDI02263)
|
|||||
Target Name |
microRNA hsa-miR-34 (MIR34)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Liver cancer [ICD-11: 2C12] | |||||
BioChemical Class |
Non-coding RNA target
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | MRX34 | Drug Info | Phase 1 | Liver cancer | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | MRX34 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 2 | ClinicalTrials.gov (NCT01829971) A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.